Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z.

Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71. Review.

2.

[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].

Xu SN, Chen JP, Liu JP, Xia Y.

Zhong Xi Yi Jie He Xue Bao. 2009 Nov;7(11):1024-34. doi: 10.3736/jcim20091102. Review. Chinese.

PMID:
19912733
3.

What is the role of arsenic in newly diagnosed APL?

Tallman MS.

Best Pract Res Clin Haematol. 2008 Dec;21(4):659-66. doi: 10.1016/j.beha.2008.09.002. Review.

PMID:
19041605
4.

Acute promyelocytic leukemia: from highly fatal to highly curable.

Wang ZY, Chen Z.

Blood. 2008 Mar 1;111(5):2505-15. doi: 10.1182/blood-2007-07-102798. Review.

5.

Acute promyelocytic leukemia: a paradigm for differentiation therapy.

Grimwade D, Mistry AR, Solomon E, Guidez F.

Cancer Treat Res. 2010;145:219-35. doi: 10.1007/978-0-387-69259-3_13. Review.

PMID:
20306254
6.

Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy.

Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ, Chen Z.

Cancer Biol Ther. 2002 Nov-Dec;1(6):614-20. Review.

PMID:
12642682
7.

Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.

Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z.

J Intern Med. 2015 Dec;278(6):627-42. doi: 10.1111/joim.12376. Epub 2015 Jun 9. Review.

8.

Understanding the molecular pathogenesis of acute promyelocytic leukemia.

Lo-Coco F, Hasan SK.

Best Pract Res Clin Haematol. 2014 Mar;27(1):3-9. doi: 10.1016/j.beha.2014.04.006. Epub 2014 Apr 13. Review.

PMID:
24907012
9.

PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.

Ohnishi K.

Int J Clin Oncol. 2007 Oct;12(5):313-7. Epub 2007 Oct 22. Review.

PMID:
17929112
10.

Arsenic trioxide: mechanisms of action.

Davison K, Mann KK, Miller WH Jr.

Semin Hematol. 2002 Apr;39(2 Suppl 1):3-7. Review.

PMID:
12012315
11.

Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.

Chen Z, Wang ZY, Chen SJ.

Pharmacol Ther. 1997 Oct-Dec;76(1-3):141-9. Review.

PMID:
9535176
12.

Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.

Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY.

Semin Hematol. 2001 Jan;38(1):26-36. Review.

PMID:
11172537
13.
14.

Arsenic trioxide, a therapeutic agent for APL.

Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z.

Oncogene. 2001 Oct 29;20(49):7146-53. Review.

15.

Acute promyelocytic leukemia as a paradigm for targeted therapy.

Tallman MS.

Semin Hematol. 2004 Apr;41(2 Suppl 4):27-32. Review.

PMID:
15190513
16.

Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.

Lengfelder E, Hofmann WK, Nowak D.

Leukemia. 2012 Mar;26(3):433-42. doi: 10.1038/leu.2011.245. Epub 2011 Sep 9. Review.

PMID:
21904379
17.

Molecular mechanisms of the antileukemia activities of retinoid and arsenic.

Nitto T, Sawaki K.

J Pharmacol Sci. 2014;126(3):179-85. Epub 2014 Oct 15. Review.

18.

The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.

Jing Y.

Leuk Lymphoma. 2004 Apr;45(4):639-48. Review.

PMID:
15160934
19.

Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.

Lengfelder E, Hofmann WK, Nowak D.

Expert Rev Anticancer Ther. 2013 Sep;13(9):1035-43. doi: 10.1586/14737140.2013.833681. Review.

PMID:
24053202
20.

Transcription therapy for acute promyelocytic leukaemia.

Douer D.

Expert Opin Investig Drugs. 2000 Feb;9(2):329-46. Review.

PMID:
11060680

Supplemental Content

Support Center